Aromatase Inhibition Increases Blood Pressure and Markers of Renal Injury in Female Rats.

Aromatase is a monooxygenase that catalyzes the rate-limiting step of estrogen biosynthesis from androgens. Aromatase inhibitors are widely used for treatment of patients with breast cancer. However, the effects of aromatase inhibitors on cardiovascular and renal health in females are understudied. Given that estrogen is protective against cardiovascular and kidney diseases, we hypothesized that aromatase inhibition elevates blood pressure and induces kidney injury in female Sprague Dawley rats. Twelve-week-old female rats were implanted with radio-telemetry transmitters to continuously monitor blood pressure. After baseline blood pressure recording, rats were randomly assigned to treatment with the aromatase inhibitor anastrozole (ASZ) or vehicle (Veh) in drinking water. Twenty days after treatment initiation, rats were shifted from a normal-salt (NS) to a high-salt diet (HS) for an additional 40 days. Rats were euthanized 60 days after treatment initiation. Body weight increased in both groups over the study period but the increase was greater in the ASZ-treated group. Mean arterial pressure increased in ASZ-treated rats during the NS and the HS diet phases but remained unchanged in Veh-treated rats. In addition, urinary excretion of albumin and kidney injury marker-1 and plasma urea were increased in response to aromatase inhibition. Furthermore, histological assessment revealed that ASZ treatment elevated renal tubular injury and proximal tubular brush border loss. In conclusion, chronic aromatase inhibition in vivo with ASZ increases blood pressure and markers of renal proximal tubular injury in female Sprague Dawley rats, suggesting an important role for aromatization in the maintenance cardiovascular and renal health in females.